Amplia Therapeutics Ltd

ATX

Company Profile

  • Business description

    Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

  • Contact

    350 Queen Street
    Level 17
    MelbourneVIC3000
    AUS

    T: +61 280033650

    https://www.ampliatx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,741.9026.70-0.30%
CAC 407,804.8714.600.19%
DAX 4024,304.4619.12-0.08%
Dow JONES (US)42,762.87443.131.05%
FTSE 1008,837.9126.870.30%
HKSE23,792.54114.43-0.48%
NASDAQ19,529.95231.511.20%
Nikkei 22537,741.61187.120.50%
NZX 50 Index12,563.4813.67-0.11%
S&P 5006,000.3661.061.03%
S&P/ASX 2008,515.7023.20-0.27%
SSE Composite Index3,385.361.260.04%

Market Movers